search icon
infiq-img

Infinity Pharmaceuticals Inc., Common Stock

INFIQ

PNK

$1.0E-6

+$0

(0%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$908.00
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
0
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
-3.61
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$1 L
$0 H
$1.0E-6

About Infinity Pharmaceuticals Inc., Common Stock

Infinity Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel medicines for people with cancer. The company's product candidate, including eganelisib (IPI-549), an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of metastatic triple negative breast cancer and urothelial cancer; and Phase 1/1b clinical trials for the treatment of solid tumors. Infinity Pharmaceuticals, Inc. has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company. Infinity Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Cambridge, Massachusetts. On September 29, 2023, Infinity Pharmaceuticals, Inc. along with its affiliate, a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. The plan was later approved as Chapter 11 liquidation on March 7, 2024. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameINFIQSectorS&P500
1-Week Return--1.67%1.25%
1-Month Return--3.51%1.77%
3-Month Return--4.17%9.07%
6-Month Return--10.65%5.36%
1-Year Return-99%-12.8%19.28%
3-Year Return-100%-2.49%48.86%
5-Year Return-100%21.6%88.54%
10-Year Return-100%72.94%205.26%

Financials

Dec '19Dec '20Dec '21Dec '22
Total Revenue3.05M1.72M1.86M2.59M[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":56.38,"profit":true},{"date":"2021-12-31","value":60.94,"profit":true},{"date":"2022-12-31","value":85.04,"profit":true}]
Cost of Revenue7.31M1.04M1.12M1.56M[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":14.19,"profit":true},{"date":"2021-12-31","value":15.33,"profit":true},{"date":"2022-12-31","value":21.39,"profit":true}]
Gross Profit(4.26M)682.00K738.00K1.03M[{"date":"2019-12-31","value":-413.5,"profit":false},{"date":"2020-12-31","value":66.21,"profit":true},{"date":"2021-12-31","value":71.65,"profit":true},{"date":"2022-12-31","value":100,"profit":true}]
Gross Margin(139.69%)39.67%39.72%39.72%[{"date":"2019-12-31","value":-351.65,"profit":false},{"date":"2020-12-31","value":99.88,"profit":true},{"date":"2021-12-31","value":99.99,"profit":true},{"date":"2022-12-31","value":100,"profit":true}]
Operating Expenses41.41M39.18M45.82M45.87M[{"date":"2019-12-31","value":90.26,"profit":true},{"date":"2020-12-31","value":85.41,"profit":true},{"date":"2021-12-31","value":99.88,"profit":true},{"date":"2022-12-31","value":100,"profit":true}]
Operating Income(45.66M)(38.50M)(45.08M)(44.84M)[{"date":"2019-12-31","value":-4566400000,"profit":false},{"date":"2020-12-31","value":-3849700000,"profit":false},{"date":"2021-12-31","value":-4508300000,"profit":false},{"date":"2022-12-31","value":-4484400000,"profit":false}]
Total Non-Operating Income/Expense(4.01M)(4.44M)(359.00K)295.00K[{"date":"2019-12-31","value":-1359.32,"profit":false},{"date":"2020-12-31","value":-1505.08,"profit":false},{"date":"2021-12-31","value":-121.69,"profit":false},{"date":"2022-12-31","value":100,"profit":true}]
Pre-Tax Income(47.11M)(40.49M)(45.26M)(44.37M)[{"date":"2019-12-31","value":-4711100000,"profit":false},{"date":"2020-12-31","value":-4049200000,"profit":false},{"date":"2021-12-31","value":-4526200000,"profit":false},{"date":"2022-12-31","value":-4436900000,"profit":false}]
Income Taxes(54.00K)2.44M180.00K180.00K[{"date":"2019-12-31","value":-2.21,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":7.36,"profit":true},{"date":"2022-12-31","value":7.36,"profit":true}]
Income After Taxes(47.06M)(42.94M)(45.44M)(44.55M)[{"date":"2019-12-31","value":-4705700000,"profit":false},{"date":"2020-12-31","value":-4293700000,"profit":false},{"date":"2021-12-31","value":-4544200000,"profit":false},{"date":"2022-12-31","value":-4454900000,"profit":false}]
Income From Continuous Operations(47.06M)(40.49M)(45.26M)(44.37M)[{"date":"2019-12-31","value":-4705700000,"profit":false},{"date":"2020-12-31","value":-4049200000,"profit":false},{"date":"2021-12-31","value":-4526200000,"profit":false},{"date":"2022-12-31","value":-4436900000,"profit":false}]
Income From Discontinued Operations----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true}]
Net Income(47.06M)(40.49M)(45.26M)(44.37M)[{"date":"2019-12-31","value":-4705700000,"profit":false},{"date":"2020-12-31","value":-4049200000,"profit":false},{"date":"2021-12-31","value":-4526200000,"profit":false},{"date":"2022-12-31","value":-4436900000,"profit":false}]
EPS (Diluted)(0.83)(0.68)(0.53)(0.50)[{"date":"2019-12-31","value":-83,"profit":false},{"date":"2020-12-31","value":-68,"profit":false},{"date":"2021-12-31","value":-53,"profit":false},{"date":"2022-12-31","value":-50,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

INFIQ
Cash Ratio 1.47
Current Ratio 1.65

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

INFIQ
ROA (LTM) -60.70%
ROE (LTM) 0.00%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

INFIQ
Debt Ratio Lower is generally better. Negative is bad. 2.76
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. -1.76

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

INFIQ
Trailing PE NM
Forward PE NM
P/S (TTM) 0.00
P/B 8.03
Price/FCF NM
EV/R 0.00
EV/Ebitda 0.59

FAQs

What is Infinity Pharmaceuticals Inc. share price today?

Infinity Pharmaceuticals Inc. (INFIQ) share price today is $1.0E-6

Can Indians buy Infinity Pharmaceuticals Inc. shares?

Yes, Indians can buy shares of Infinity Pharmaceuticals Inc. (INFIQ) on Vested. To buy Infinity Pharmaceuticals Inc. from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in INFIQ stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Infinity Pharmaceuticals Inc. be purchased?

Yes, you can purchase fractional shares of Infinity Pharmaceuticals Inc. (INFIQ) via the Vested app. You can start investing in Infinity Pharmaceuticals Inc. (INFIQ) with a minimum investment of $1.

How to invest in Infinity Pharmaceuticals Inc. shares from India?

You can invest in shares of Infinity Pharmaceuticals Inc. (INFIQ) via Vested in three simple steps:

  • Click on Sign Up or Invest in INFIQ stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Infinity Pharmaceuticals Inc. shares
What is Infinity Pharmaceuticals Inc. price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Infinity Pharmaceuticals Inc. (INFIQ) is 8.03

What is the Market Cap of Infinity Pharmaceuticals Inc.?

The market capitalization of Infinity Pharmaceuticals Inc. (INFIQ) is $908.00

What is Infinity Pharmaceuticals Inc.’s stock symbol?

The stock symbol (or ticker) of Infinity Pharmaceuticals Inc. is INFIQ

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top